EXECUTIVE SUMMARY

MARKET OVERVIEW Health and Wellbeing

Estimated European Health and Wellbeing Market Value in 2020 £135.7 billion (Source: Statista)

Overwhelming Public awareness of the benefits of Cannabis based food supplements and wellness products

Using the Most Advanced and Natural Processing techniques, is introducing a wellness ‘system’ in the form of complimentary products that help ensure a balanced intake of CBD

Medicaleaf have invested heavily in cutting edge technology that drives our intuitive e-commerce platform which talks to customers via our ‘Intelligent Avatar’

Medicaleaf plan to launch the most energetic Marketing and Awareness campaign in the Health and Wellness sector EXPECTATIONS Forecast From a standing start, Medicaleaf™ intends to generate revenue in excess of £5.34 million in this first trading year, with sales increasing by 372% in year two and a further 88% in year three as the ‘demand-supply’ equation is successfully welded. Despite substantial start-up expenditure, partly due to infrastructure build and partly due to brand investment, the Company expects to return a modest profit in its first year and a substantial profit in its second year of trading with profits increasing anywhere between 60 to 100% year on year on a net profit over sales metric of ‘plus 43%’. Brand amplified by seasoned marketing team using cutting edge social media, pop-up stores, advocacy, P.R. and Partnerships to mention but a few strategies

Medicinal Cannabis: Forecast Medical Cannabis Market Value 2028 £49.52 billion (Source: Prohibition Partners)

Building a UK Network of ‘Best Practice’ medical centres where specialists can prescribe or oversee prescriptions of Medicinal Cannabis

Working with NHS and NIHR to trial a unique and patented prescription technology that optimises Medicinal Cannabis doses, de-risks process, and builds confidence in the future of Medicinal Cannabis

Patented Technology securely builds knowledge of the individual’s needs as well as powerful

evidential meta-data

CONFIDENTIAL - DO NOT DISSEMINATE. This business plan contains confidential, trade-secret information and is shared only with the understanding that you will not share its contents or ideas with third parties without the express written consent of the plan author. CONFIDENTIAL - DO NOT DISSEMINATE. This business plan contains confidential, trade-secret information and is shared only with the understanding that you will not share its contents or ideas with third parties without the express written consent of the plan author.

Finance Requirement Medicaleaf ™ is looking for up to £10 million initial investment. Capital raised will be invested in Product Manufacturing, Sales and Marketing campaigns and distribution infrastructure but will also be used for suitable acquisitions and joint ventures that will catapult the growth of the company in suitable strategic moves. Such inorganic growth is as yet unknown and as such excluded from any forecasts. Medicaleaf ™ will have a ‘post-raise’ valuation of £20 million with expectations to reach a pre-floatation valuation of £200 million in three years’ time. New investor capital will represent up to 50% of voting rights. Management has EIS Advance Assurance with HMRC so we anticipate eligible investors will be able to gain EIS relief in the current or previous tax year. Exit Strategy Current strategy is to float Medicaleaf™ on the Alternative Investment Market in approximately three years’ time when Medicaleaf™ share values will have been given a further boost as a result of anticipated liberalization by HM Government of the UK licensing system for Medical Cannabis production and prescription in the UK although a merger with a quoted company cannot be ruled out and will give a speedier exit for investors wishing to do so. By this time Medicaleaf ™ will have well-honed brands for both the Medical and Wellness segments of the market and a firm grip of the recognized UK and European Distribution Channels.

MEDICALEAF FINANCIAL PERFORMANCE

Sales Direct Costs Gross Profit

GP%

CONFIDENTIAL - DO NOT DISSEMINATE. This business plan contains confidential, trade-secret information and is shared only with the understanding that you will not share its contents or ideas with third parties without the express written consent of the plan author.